Clinical Research Directory
Browse clinical research sites, groups, and studies.
OM336 in Autoimmune Cytopenias
Sponsor: Ouro Medicines
Summary
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.
Official title: An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants With Active Autoimmune Cytopenias
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2025-08-01
Completion Date
2027-09
Last Updated
2025-09-30
Healthy Volunteers
No
Conditions
Interventions
OM336
OM336 is an engineered bispecific antibody directed against BCMA and CD3
Locations (3)
The Canberra Hospital
Canberra, Australian Capital Territory, Australia
Liverpool Hospital
Sydney, New South Wales, Australia
Icon Cancer Center South Brisbane
Brisbane, Queensland, Australia